IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) will present updated clinical data on its melanoma drug darovasertib at the ESMO Congress 2026 from October 23-27 in Madrid, Spain. The presentation will include Phase 2 expansion data from the OptimUM-01 study for HLA-A*02:01-positive metastatic uveal melanoma patients, subgroup analyses from the OptimUM-02 trial for HLA-A*02:01-negative patients, and follow-up data from the OptimUM-09 trial for primary uveal melanoma.